These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
303 related articles for article (PubMed ID: 30466749)
21. Efficacy of Targeted Immunotherapy as Induction or Salvage Therapy in Acute Lymphoblastic Leukemia: A Systematic Review and Meta-Analysis. Ponvilawan B; Vittayawacharin P; Tunsing P; Owattanapanich W Technol Cancer Res Treat; 2021; 20():15330338211037434. PubMed ID: 34350787 [TBL] [Abstract][Full Text] [Related]
26. Clinical trial update on bispecific antibodies, antibody-drug conjugates, and antibody-containing regimens for acute lymphoblastic leukemia. Liu D; Zhao J; Song Y; Luo X; Yang T J Hematol Oncol; 2019 Feb; 12(1):15. PubMed ID: 30736842 [TBL] [Abstract][Full Text] [Related]
27. How should we treat older adults with Ph+ adult ALL and what novel approaches are being investigated? Wieduwilt MJ Best Pract Res Clin Haematol; 2017 Sep; 30(3):201-211. PubMed ID: 29050693 [TBL] [Abstract][Full Text] [Related]
28. Emerging role of immunotherapy in precursor B-cell acute lymphoblastic leukemia. Valecha GK; Ibrahim U; Ghanem S; Asti D; Atallah JP; Terjanian T Expert Rev Hematol; 2017 Sep; 10(9):783-799. PubMed ID: 28666090 [TBL] [Abstract][Full Text] [Related]
30. No free rides: management of toxicities of novel immunotherapies in ALL, including financial. Jain T; Litzow MR Blood Adv; 2018 Nov; 2(22):3393-3403. PubMed ID: 30482769 [TBL] [Abstract][Full Text] [Related]
31. Sequential therapy with inotuzumab ozogamicin, CD19 CAR T cells, and blinatumomab in an elderly patient with relapsed acute lymphoblastic leukemia. Wullenkord R; Reicherts C; Mikesch JH; Marx J; Wethmar K; Albring J; Call S; Lenz G; Stelljes M Ann Hematol; 2021 Feb; 100(2):587-589. PubMed ID: 32829460 [No Abstract] [Full Text] [Related]
32. SOHO State of the Art Update and Next Questions: Advances in the Treatment of Adult Acute Lymphoblastic Leukemia. Paul S; Rausch CR; Welch MA; Kantarjian HM; Jabbour EJ Clin Lymphoma Myeloma Leuk; 2019 Aug; 19(8):471-479. PubMed ID: 31307896 [TBL] [Abstract][Full Text] [Related]
33. Humoral and cellular immunotherapy in ALL in children, adolescents, and young adults. Hochberg J; El-Mallawany NK; Cairo MS Clin Lymphoma Myeloma Leuk; 2014 Sep; 14 Suppl():S6-13. PubMed ID: 25486958 [TBL] [Abstract][Full Text] [Related]
34. Novel monoclonal antibody-based treatment strategies in adults with acute lymphoblastic leukemia. Guerra VA; Jabbour EJ; Ravandi F; Kantarjian H; Short NJ Ther Adv Hematol; 2019; 10():2040620719849496. PubMed ID: 31205644 [TBL] [Abstract][Full Text] [Related]
35. Inotuzumab ozogamicin: a CD22 mAb-drug conjugate for adult relapsed or refractory B-cell precursor acute lymphoblastic leukemia. Yurkiewicz IR; Muffly L; Liedtke M Drug Des Devel Ther; 2018; 12():2293-2300. PubMed ID: 30087554 [TBL] [Abstract][Full Text] [Related]
37. No free rides: management of toxicities of novel immunotherapies in ALL, including financial. Jain T; Litzow MR Hematology Am Soc Hematol Educ Program; 2018 Nov; 2018(1):25-34. PubMed ID: 30504288 [TBL] [Abstract][Full Text] [Related]
38. Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival. Topp MS; Kufer P; Gökbuget N; Goebeler M; Klinger M; Neumann S; Horst HA; Raff T; Viardot A; Schmid M; Stelljes M; Schaich M; Degenhard E; Köhne-Volland R; Brüggemann M; Ottmann O; Pfeifer H; Burmeister T; Nagorsen D; Schmidt M; Lutterbuese R; Reinhardt C; Baeuerle PA; Kneba M; Einsele H; Riethmüller G; Hoelzer D; Zugmaier G; Bargou RC J Clin Oncol; 2011 Jun; 29(18):2493-8. PubMed ID: 21576633 [TBL] [Abstract][Full Text] [Related]